← Back to Search

Other

PPE and Training for Silicosis

N/A
Waitlist Available
Led By William Checkley, MD, PhD
Research Sponsored by Johns Hopkins University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Cognitively capable to provide informed consent
Age 18 years or older
Must not have
Less than 18 years old
Not cognitively capable to provide informed consent
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights
No Placebo-Only Group

Summary

This trial aims to protect brick kiln workers in Nepal from silicosis by giving them respirators and training them on how to use these devices. The study will assess workers' current knowledge, design a training program, and test its effectiveness in reducing silica exposure.

Who is the study for?
This trial is for adult brick kiln workers in Bhaktapur, Nepal who are at risk of silicosis due to silica exposure. Participants must be over 18 years old and able to give informed consent. It excludes those not working in brick kilns, under 18, or unable to consent.
What is being tested?
The study tests a training program on using personal protective equipment (PPE) like N95 respirators and protective eyewear to reduce silica inhalation among workers. The intervention includes a workshop designed with the Discover, Design, Build, Test framework.
What are the potential side effects?
There may be no direct medical side effects from participating as this trial focuses on educational interventions and PPE use. However, discomfort or difficulty wearing PPE such as respirators could occur.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am mentally able to understand and agree to the study's procedures.
Select...
I am 18 years old or older.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am under 18 years old.
Select...
I am unable to understand and give consent for treatment.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Feasibility as assessed by The Feasibility of Intervention Measure (FIM) score

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

4Treatment groups
Experimental Treatment
Group I: Pilot Study: Personal Protective Equipment Training ProgramExperimental Treatment2 Interventions
A small training program will be offered to brick kiln workers to determine preferred PPE type, feasibility in the work environment and proper usage of PPE.
Group II: Feedback Workshop on Pilot Personal Protective Equipment Training ProgramExperimental Treatment1 Intervention
Group III: Design of Personal Protective Equipment Training WorkshopExperimental Treatment1 Intervention
Group IV: Baseline Survey: Silicosis and Personal Protective EquipmentExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
N95 Respirator
2019
N/A
~3050
Protective Eyewear
2024
N/A
~100

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for silicosis include the use of respirators to prevent silica inhalation, bronchodilators to ease breathing, and corticosteroids to reduce inflammation. Respirators act as a physical barrier, preventing silica particles from entering the lungs, which is crucial in halting the progression of the disease. Bronchodilators help to open the airways, making it easier for patients to breathe, while corticosteroids reduce lung inflammation, alleviating symptoms and preventing further lung damage. These treatments are vital for silicosis patients as they address both the prevention of further silica exposure and the management of existing symptoms, thereby improving quality of life and reducing the risk of severe complications.
[Aerosol therapy].Short-acting inhaled bronchodilators for cystic fibrosis.Continuous infusion aerosol delivery of prostacyclins during mechanical ventilation: challenges, limitations, and recent advances.

Find a Location

Who is running the clinical trial?

Chiesi FoundationUNKNOWN
2 Previous Clinical Trials
316 Total Patients Enrolled
Fogarty International Center of the National Institute of HealthNIH
151 Previous Clinical Trials
171,429 Total Patients Enrolled
Johns Hopkins UniversityLead Sponsor
2,321 Previous Clinical Trials
14,873,843 Total Patients Enrolled
~56 spots leftby Nov 2025